Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) EBITDA (2016 - 2025)

Historic EBITDA for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to -$1.2 million.

  • Abvc Biopharma's EBITDA fell 23570.69% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year decrease of 963.61%. This contributed to the annual value of -$5.0 million for FY2024, which is 3614.41% up from last year.
  • Latest data reveals that Abvc Biopharma reported EBITDA of -$1.2 million as of Q3 2025, which was down 23570.69% from -$2.2 million recorded in Q2 2025.
  • Abvc Biopharma's 5-year EBITDA high stood at -$370346.0 for Q3 2024, and its period low was -$8.4 million during Q4 2021.
  • Over the past 5 years, Abvc Biopharma's median EBITDA value was -$1.8 million (recorded in 2023), while the average stood at -$2.4 million.
  • In the last 5 years, Abvc Biopharma's EBITDA crashed by 45922.51% in 2022 and then skyrocketed by 9134.36% in 2023.
  • Abvc Biopharma's EBITDA (Quarter) stood at -$8.4 million in 2021, then surged by 46.74% to -$4.5 million in 2022, then surged by 91.34% to -$386064.0 in 2023, then crashed by 94.22% to -$749822.0 in 2024, then crashed by 65.81% to -$1.2 million in 2025.
  • Its EBITDA stands at -$1.2 million for Q3 2025, versus -$2.2 million for Q2 2025 and -$843568.0 for Q1 2025.